An Update on Molecular Biology of Cutaneous T Cell Lymphoma

Walia, Ritika; Yeung, Cecilia C.S.

doi:10.3389/fonc.2019.01558

Cited by 24 publications

(26 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A dominant T-cell clone in the blood is detected in a large majority of L-HES cases [23,25], and atypical T cells often exceed 70% of circulating lymphocytes [30]. While clonal T-cell populations can occasionally be detected in BIDs, they are not typical, nor a defining feature [12]. BIDs are characterized by polyclonal infiltrates of reactive T cells, and are not considered cutaneous lymphoproliferative disorders [31,32].…”

Section: Introductionmentioning

confidence: 99%

“…Gene expression biomarkers have enormous potential to improve clinical practice for MF/SS, and innovative efforts have been taken to identify sensitive and specific diagnostic and prognostic biomarkers [ 9 , 10 , 11 , 12 ]. Studies have employed “disease controls” like psoriasis and atopic dermatitis to filter out gene expression signals contributed by inflammatory processes [ 11 , 13 , 14 , 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome

Moerman-Herzog

Mehdi

Wong

2020

Cells

View full text Add to dashboard Cite

Sézary syndrome (SS), an aggressive cutaneous T-cell lymphoma (CTCL) with poor prognosis, is characterized by the clinical hallmarks of circulating malignant T cells, erythroderma and lymphadenopathy. However, highly variable clinical skin manifestations and similarities with benign mimickers can lead to significant diagnostic delay and inappropriate therapy that can lead to disease progression and mortality. SS has been the focus of numerous transcriptomic-profiling studies to identify sensitive and specific diagnostic and prognostic biomarkers. Benign inflammatory disease controls (e.g., psoriasis, atopic dermatitis) have served to identify chronic inflammatory phenotypes in gene expression profiles, but provide limited insight into the lymphoproliferative and oncogenic roles of abnormal gene expression in SS. This perspective was recently clarified by a transcriptome meta-analysis comparing SS and lymphocytic-variant hypereosinophilic syndrome, a benign yet often clonal T-cell lymphoproliferation, with clinical features similar to SS. Here we review the rationale for selecting lymphocytic-variant hypereosinophilic syndrome (L-HES) as a disease control for SS, and discuss differentially expressed genes that may distinguish benign from malignant lymphoproliferative phenotypes, including additional context from prior gene expression studies to improve understanding of genes important in SS.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome

Moerman-Herzog

Mehdi

Wong

2020

Cells

View full text Add to dashboard Cite

show abstract

“…Activation of AKT has also been implicated to occur in CTCL through mutations in the PI3K pathway relating to TCR-CD28 [209] . NF-κB pathway activity has also been shown to be increased in CTCL [206] . The canonical NF-κB pathway occurs as follows.…”

Section: Malignant Cell Growthmentioning

confidence: 98%

“…Mutations upregulating the Janus kinase (JAK) and signal transducer and activator of transcription proteins (STAT) are implicated in CTCL. JAK1, JAK3, STAT3, and STAT5B are mutated in certain CTCL cell lines [206] . Mutations in JAK1, JAK3, and STAT5B have also been implicated in T-cell prolymphocytic leukemia [207] .…”

Section: Malignant Cell Growthmentioning

confidence: 99%

Overview of genetic signaling pathway interactions within cutaneous malignancies

Maner¹,

Dupuis²,

Su³

et al. 2020

JCMT

View full text Add to dashboard Cite

Melanoma and non-melanoma cutaneous malignancies are some of the leading causes of cancer-related death in the United States. Though melanoma is more known to have a high mortality rate, the total mortality per year is nearly equal for between melanoma and non-melanoma skin cancer. Moreover, the non-melanoma types of cutaneous malignancies have potential to become locally invasive and even metastasize with very little to no treatment options when advanced. The development of these malignancies involves various genetic pathways through the four hallmarks of cancer development: malignant cell growth, apoptosis evasion, the use of supporting stroma and vascularization, and modulating and promoting an inadequate immune response. The genetic signaling pathways of basal cell carcinoma, squamous cell carcinoma, verrucous carcinoma, basosquamous cell carcinoma, melanoma, and cutaneous T-cell lymphoma interact with each other through genetic predisposition as well as with environmental exposures. Furthermore, solar ultraviolet radiation and chronic inflammatory states are found to initiate the progression of many of these cutaneous malignancies. This paper includes validated models of genetic pathways, emerging pathways, and crosstalk between genetic pathways through the four hallmarks of cancer development. Moreover, unlike most reviews addressing oncogenetics of the well-recognized, as well as newly dynamic, interrelated, interactive, complex, and adaptive flux states.

show abstract

“…Moreover, they differ in prognosis and treatment from systemic lymphomas with similar histological features [ 5 , 6 , 7 , 8 ]. Up to 75–80% of cutaneous lymphomas originate from T-cells, and only 20–25% from B-cells [ 9 , 10 , 11 ]. Many subtypes of cutaneous T-cell lymphomas were described, and the most common ones are mycosis fungoides and Sézary syndrome.…”

Section: Introductionmentioning

confidence: 99%

Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP

et al. 2020

View full text Add to dashboard Cite

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas. The rarity of primary cutaneous PTCL-NOS means that there is a paucity of data regarding clinical and histopathological features and its clinical course. This malignancy is an aggressive and life-threatening hematological malignancy that often presents mimicking other less severe plaque-like skin conditions. Due to the nonspecific nature of these lesions, CD4-positive cutaneous T-cell lymphoma (CTCL) is often misdiagnosed as either mycosis fungoides or Sezary syndrome. We describe a patient who presented with a large tumoral mass in the right frontal area, with involvement of the right upper eyelid and the ocular globe, causing loss of vision greatly impacting the quality of life. Biopsy revealed primary cutaneous PTCL-NOS, treated successfully with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide combination chemotherapy. As elderly patients are indicated to receive attenuated doses of chemotherapy, CHOP-based regimens represent viable options.

show abstract

An Update on Molecular Biology of Cutaneous T Cell Lymphoma

Cited by 24 publications

References 100 publications

Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome

Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome

Overview of genetic signaling pathway interactions within cutaneous malignancies

Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid, Following Combination Chemotherapy with Etoposide Plus COP

Contact Info

Product

Resources

About